Results 1 to 10 of about 12,025 (204)

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD. [PDF]

Int J Chron Obstruct Pulmon Dis, 2018
Anthony D D’Urzo,1 Peter Kardos,2 Russell Wiseman3 1Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, ON, Canada; 2Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau ...
D'Urzo AD, Kardos P, Wiseman R.
europepmc   +9 more sources

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis. [PDF]

BMC Pulm Med, 2020
Background Revefenacin, a once-daily, long-acting muscarinic antagonist delivered via standard jet nebulizer, increased trough forced expiratory volume in 1 s (FEV1) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in
Donohue JF, Kerwin E, Barnes CN, Moran EJ, Haumann B, Crater GD.   +5 more
europepmc   +2 more sources

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD. [PDF]

Sci Rep, 2023
Few studies have directly compared the incidence of pneumonia in patients on common chronic obstructive pulmonary disease (COPD) treatments such as long-acting muscarinic antagonists (LAMA) with those on inhaled corticosteroids and long-acting β2-agonist
Lee EG, Kim Y, Hwang YI, Yoo KH, Lee SE, Jung KY, Lee D, Park YB, Rhee CK.   +8 more
europepmc   +2 more sources

Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. [PDF]

Int J Chron Obstruct Pulmon Dis, 2015
Afisi Segun Ismaila,1,2 Eline L Huisman,3 Yogesh Suresh Punekar,4 Andreas Karabis31Value Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA; 2Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; 3Real ...
Ismaila AS, Huisman EL, Punekar YS, Karabis A.   +3 more
europepmc   +2 more sources

Self-directed de-escalation of maintenance inhaler therapy in patients with severe asthma in remission with biologic treatment: An observational study. [PDF]

J Allergy Clin Immunol Glob
Background: mAbs targeting type 2 inflammation have significantly improved disease control in severe asthma. As more patients achieve clinical stability, the safety and outcomes of maintenance inhaled therapy (MIT) de-escalation have become clinically ...
Benfante A, Tomasello A, Catanzaro V, Gentile L, Togias A, Scichilone N.   +5 more
europepmc   +2 more sources

Therapeutic effect of long-acting muscarinic antagonist for treating uncontrolled asthma assessed using impulse oscillometry. [PDF]

Respir Res
Background In recent years, the incorporation of LAMAs into asthma therapy has been expected to enhance symptom control. However, a significant number of patients with asthma continue to experience poorly managed symptoms.
Sugawara H, Saito A, Yokoyama S, Chiba H.   +3 more
europepmc   +2 more sources

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit

International Journal of COPD, 2012
Charlotte Suppli UlrikDepartment of Pulmonary Medicine, Hvidovre Hospital and University of Copenhagen, Copenhagen, DenmarkBackground: Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive ...
Ulrik CS
doaj   +2 more sources

Single inhaler triple therapy in COPD – all that glitters is not gold

Monaldi Archives for Chest Disease, 2021
Dear Editor, The recent studies on combination triple therapy of inhaled corticosteroid, long acting beta2 agonist and long-acting muscarinic antagonist (ICS-LABA-LAMA) in COPD have consistently demonstrated an improvement in exacerbation frequency and/
Kartik Deshmukh, Arjun Khanna
doaj   +1 more source

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea [PDF]

Tuberculosis and Respiratory Diseases, 2021
Background Many chronic obstructive pulmonary disease (COPD) patients receiving monotherapy continue to experience symptoms, exacerbations and poor quality of life.
Sang Haak Lee, Chin Kook Rhee, Kwangha Yoo, Jeong Woong Park, Suk Joong Yong, Jusang Kim, Taehoon Lee, Seong Yong Lim, Ji-Hyun Lee, Hye Yun Park, Minyoung Moon, Ki-Suck Jung   +11 more
doaj   +1 more source

Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators

Respiratory Medicine Case Reports, 2019
Immune checkpoint inhibitors (ICIs) have been used to treat lung cancer. Several types of ICI-related interstitial lung diseases have been reported, including organizing pneumonia, non-specific interstitial pneumonia, and diffuse alveolar damage. However,
Takafumi Yamaya, Hwang Moon Hee, Takayuki Aoyagi, Tatsuya Ogimoto, Naoki Yamada, Ryoichi Ishikawa, Erika Nakai, Kenta Nishi, Chie Yoshimura, Yasuo Nishizaka   +9 more
doaj   +1 more source